1201675-01-5 Usage
Uses
Used in Pharmaceutical Industry:
2,6-Dichloro-4-(difluoromethyl)pyridine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of active ingredients. It contributes to the development of new drugs by providing a stable and reactive platform for further chemical modifications.
Used in Agrochemical Industry:
In the agrochemical sector, 2,6-Dichloro-4-(difluoromethyl)pyridine is utilized as a building block in the production of active ingredients for pesticides, herbicides, and fungicides. Its presence in these compounds aids in enhancing the effectiveness of these products in controlling and preventing crop diseases and pests.
Used in Heterocyclic Compound Synthesis:
2,6-Dichloro-4-(difluoromethyl)pyridine also serves as a starting material for the synthesis of other heterocyclic compounds, which are important in various chemical and pharmaceutical applications. Its unique structure allows for the creation of diverse and complex molecular entities with potential uses in different industries.
Safety Note:
While 2,6-Dichloro-4-(difluoromethyl)pyridine has been found to exhibit low acute toxicity and limited evidence of chronic toxicity, it is essential to adhere to proper handling and storage procedures to ensure the safety of individuals and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 1201675-01-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,1,6,7 and 5 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1201675-01:
(9*1)+(8*2)+(7*0)+(6*1)+(5*6)+(4*7)+(3*5)+(2*0)+(1*1)=105
105 % 10 = 5
So 1201675-01-5 is a valid CAS Registry Number.
1201675-01-5Relevant academic research and scientific papers
Methylpyrazole derivatives as RET inhibitor
-
Paragraph 0911-0915, (2021/07/21)
The invention relates to a methylpyrazole derivative as an RET inhibitor, in particular to a compound as shown in a formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof. The compound of the formula (I) can be used for preventing or treating diseases mediated by abnormal RET activity.
CYCLIC COMPOUNDS AND METHODS OF USING SAME
-
Page/Page column 582, (2021/07/02)
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.
2 Tyrosine kinase mediated signal transduction inhibitors
-
, (2019/09/17)
Disclosed herein are compounds of Formula (), and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, X, X, X, X, X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER
-
Page/Page column 79, (2010/01/07)
The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.
